Chemocentryx, Inc.

Metabasis Therapeutics, Inc.

Abbvie Inc.

Venkat Reddy Mali

Penglie Zhang

Ju Yang

Sreenivas Punna

Christopher W Lange

Viengkham Malathong

Manmohan Reddy Leleti

Hiroko Tanaka

Rajinder Paul Singh

Yibin Zeng

Jay Patrick Powers

Pingchen Fan

Junfa Fan

Rebecca M Lui

Jeffrey P McMahon

Yandong Li

Jaroslaw Kalisiak

Dean R Dragoli

Chao Yu

Scott J Hecker

Serge H Boyer

Antoni Krasinski

Xi Chen

Trevor T Charvat

Qun Dang

Darren J McMurtrie

K Raja Reddy

Robert Huerta Lemus

Zhili Sun

Haiqing Li

Jorge E Gomez-Galeno

Matthew P Grote

Thanh Huu Nguyen

William Craigo

Paul D Van Poelje

Mingwei Chen

Mark D Erion

Raja K Reddy

Daniel J Dairaghi

Brett C Bookser

Nicholas Brian Raffaele

Howard S Roth

Joanne Tan

Matthew J Walters

Jeff Stebbins

Valentino J Stella

Shichang Miao

Yang Song

Jeffrey P McMAHON

Yu Wang

James J Campbell

Karen Ebsworth

Shijie Li

Kevin R Woller

Zhiguo Bian

XingYu Jiang

Matthew H Katcher

Rajinder Singh

Jeffrey Mcmahon

Zhaozhong J Jia

Alexey A Rivkin

Ashley M Adams

Joshua N Payette

Shahab Mortezaei

Jason P Burke

Violeta L Marin

Elizabeth L Noey

Jeffrey P MacMahon

Jarek Kalisiak

Jeffrey P Mcmahon

Hiroko Tankaka

Daniel Dairaghi

The present disclosure provides, inter alia, Compounds of Formula (I) or pharmaceutically acceptable salts thereof that are modulators of the C5a receptor. Also provided are pharmaceutical compositions and methods of use including the treatment of diseases or disorders involving pathologic activation from C5a and non-pharmaceutical applications.

Diaryl substituted 6,5-fused ring compounds as C5aR inhibitors

The present invention provides for compounds of formula (I) wherein R, R, R, R, R, and R, are as defined herein, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of CLL.

Pyrimidines for degrading Bruton's tyrosine kinase

Compounds are provided that are modulators of the CCR2 receptor. The compounds have the general formula (Ia1′): and are useful in pharmaceutical compositions, methods for the treatment of diseases and disorders involving the pathologic activation of CCR2 receptors.

Substituted tetrahydropyrans as CCR2 modulators

The present disclosure is drawn to the combination therapy of a C-C Chemokine Receptor 4 (CCR4) antagonist and one or more immune checkpoint inhibitors in the treatment of cancer.

Combination therapy using C—C chemokine receptor 4 (CCR4) antagonists and one or more immune checkpoint inhibitors

Compounds are provided as inhibitors of CXCR2, having the structure:

Inhibitors of CXCR2

Aniline compounds are provided which bind to CCR(4) and are useful for the treatment of diseases such as allergic diseases, autoimmune diseases, graft rejection and cancer.

Substituted anilines as CCR(4) antagonists

Compounds represented by Formula (I) or (II): are provided herein, or a pharmaceutically acceptable salt, or a prodrug or bioisostere thereof; wherein R, R, R, R, R, R, R, R, R, R, R, R, R, R, R, R, R, Y, Y′, and the subscripts m and n are as defined herein.

Indanes as PD-L1 inhibitors

Compounds are provided as chemokine inhibitors having the structure:

Modulators of chemokine receptors

Compounds are provided to modulate the C5a receptor. The compounds have the following Formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R, Rand Rare as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

Deuterated compounds as immunomodulators

6-5 fused rings as C5a inhibitors

Compounds are provided that are useful as immunomodulators. The compounds have the following Formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein Z, L, R, R, R, R, R, R, R, R, R, R, R, R, m and n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

Immunomodulator compounds

The present disclosure provides, inter alia, methods of treating generalized pustular psoriasis (GPP) by administering an effective amount of a Chemokine Receptor 6 (CCR6) antagonist and/or a C-X-C motif chemokine receptor 2 (CXCR2) antagonist. Also provided herein are methods of modulating dysregulated IL-36 signaling in a subject in need thereof and methods of reducing neutrophil, inflammatory dendritic cell (iDC), and/or CD4 T cell accumulation in a subject in need thereof, said methods, include dministering an effective amount of a Chemokine Receptor 6 (CCR6) antagonist and/or a C-X-C motif chemokine receptor 2 (CXCR2) antagonist. In some embodiments, the CCR6 and/or CXCR2 antagonist has the formula:

Methods of treating generalized pustular psoriasis with an antagonist of CCR6 or CXCR2

The present disclosure provides, inter alia, Compounds of Formulae IA, IB, IC, IIA, IIB and IIC or pharmaceutically acceptable salts thereof that are modulators of the C5a receptor. Also provided are pharmaceutical compositions and methods of use including the treatment of diseases or disorders involving pathologic activation from C5a and non-pharmaceutical applications. 

Prodrugs of fused-bicyclic C5aR antagonists

Compounds are provided that are useful as immunomodulators. The compounds have the Formula (I) including stereoisomers and pharmaceutically acceptable salts thereof, wherein R, R, R, R, R, R, R, R, R, R, R, R, Rand the subscript n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

Compounds for treatment of PD-L1 diseases

Diaryl substituted 5,5-fused ring compounds as C5aR inhibitors

Growing community of inventors

Cupertino, CA, United States of America

Venkat Reddy Mali